title: [Propranolol in the treatment of infantile haemangioma in Tunisia].
authors.forename: N
authors.initials: N
authors.lastname: El Fekih
authors.forename: W
authors.initials: W
authors.lastname: Hafsi
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: N
authors.initials: N
authors.lastname: Zine
authors.forename: A
authors.initials: A
authors.lastname: Khaled
authors.forename: F
authors.initials: F
authors.lastname: Zeglaoui
authors.forename: B
authors.initials: B
authors.lastname: Fazaa
mesh_terms: D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016896:Treatment Outcome; D014416:Tunisia; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014717:Vertigo / Q000139:chemically induced
chemical_list: D014662:Vasoconstrictor Agents; D011433:Propranolol